GLP-1 receptor agonism in prostate cancer: insights and perspectives
- Dettagli
- Creato: Sabato, 10 Ottobre 2026 10:46
- Visite: 38
GLP-1 receptor agonism in prostate cancer: insights and perspectives
S. La Vignera, R.A. Condorelli
Metabolic context and clinical relevance
Men with prostate cancer frequently receive androgen deprivation therapy (ADT), which is associated with significant metabolic adverse effects, including insulin resistance, type 2 diabetes mellitus, and increased cardiovascular morbidity (2). In this clinical context, GLP-1 receptor agonists (GLP-1 RAs) – particularly semaglutide – have demonstrated robust cardiometabolic benefits in large randomised trials, independent of glycaemic status (3, 4). The question of whether GLP-1 RAs might exert direct antitumour activity in prostate tissue, independently of their systemic metabolic effects, is therefore highly relevant for the management of patients with prostate cancer who receive ADT or who progress to castration-resistant disease...